Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

ables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and other factors described under the caption "Risk Factors That May Affect Future Results" in the Company's Quarterly Report on Form 10-Q for the period ending September 30, 2009.  Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  New factors emerge from time to time and it is not possible for the Company to predict which will arise.  In addition, the Company cannot assess the impact of each factor on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex 2008 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the U.S. Securities and Exchange Commission.  The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Cambrex

Cambrex provides products and services to accelerate the development and commercialization of small molecule therapeutics including APIs, advanced intermediates, enhanced drug delivery, and other products for branded and generic pharmaceuticals.  The Company currently employs approximately 850 people worldwide.  For more information, please visit

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 2014 According to a new ... - Global Industry Analysis, Size, Share, Growth, Trends and ... USD 25.16 billion in 2013, which is expected to ... CAGR of 10.4% from 2014 to 2020. ... Increasing demand for accurate early diagnosis and ...
(Date:8/1/2014)... Once a decision has been made to increase ... how to define your tolerance for lowest cost design ... Director of Facilities Integration at Fluor Industrial Services, Craig ... and special guest Carrier Li, Director in Global Asset ... provide an examination of the Conceptual Design process and ...
(Date:8/1/2014)... 2014 Cambrex Corporation (NYSE: CBM ) ... Highlights , Second quarter sales ... same period last year. , Second quarter EBITDA increased ... same period last year (see table at the end of ... excluding the impact of foreign currency, to between 13% and ...
(Date:8/1/2014)... Testing the mechanical properties of ... understanding embryonic development. How and why embryonic ... functionally distinct tissues is important because abnormalities can ... McDevitt, Melissa Kinney, and Rabbia Saeed worked from ... cues to control many aspects of embryo development. ...
Breaking Biology Technology:Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 2Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 3Global Biophotonics Market is Expected to Reach USD 50.20 Billion in 2020: Transparency Market Research 4Defining Low Cost in Your Solution for Future Facilities, New Webinar for Pharma, Biotech, Medical Device and Healthcare Companies, Hosted by Xtalks 2Cambrex Reports Second Quarter 2014 Financial Results 2Cambrex Reports Second Quarter 2014 Financial Results 3Cambrex Reports Second Quarter 2014 Financial Results 4Cambrex Reports Second Quarter 2014 Financial Results 5Cambrex Reports Second Quarter 2014 Financial Results 6Cambrex Reports Second Quarter 2014 Financial Results 7Cambrex Reports Second Quarter 2014 Financial Results 8Cambrex Reports Second Quarter 2014 Financial Results 9Cambrex Reports Second Quarter 2014 Financial Results 10Cambrex Reports Second Quarter 2014 Financial Results 11Cambrex Reports Second Quarter 2014 Financial Results 12Cambrex Reports Second Quarter 2014 Financial Results 13Cambrex Reports Second Quarter 2014 Financial Results 14Cambrex Reports Second Quarter 2014 Financial Results 15Cambrex Reports Second Quarter 2014 Financial Results 16Study Links Biomechanics and Gene Expression in Stem Cells 2
... TOKYO, Oct. 22 /Xinhua-PRNewswire/ -- Olympus Capital Holdings ... reached an agreement to,sell Arysta LifeScience Corporation, the ... for an enterprise value of,approximately JPY 250 billion ... for Olympus Capital, a leading middle market private,equity ...
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... be Webcast as Part of AACR Virtual Meeting -, ... RGDX ) today announced that Kathleen Danenberg, the ... on the role,of pharmacogenomics in tailoring medicine at the ... will be held October 22-26, 2007 at the Moscone ...
Cached Biology Technology:Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3
(Date:8/1/2014)... The Journal of Nutrition Education and Behavior (JNEB) announces ... (GEM) awards, which were presented at the Society for ... Impact: Local to Global," in Milwaukee, Wisconsin, June 28 ... the authors of the best article and best GEM ... of the JNEB Journal Committee and Board of Editors. ...
(Date:8/1/2014)... of a new study, including two Simon Fraser ... industry representatives and policymakers must collaborate closely on ... gas development. Viorel Popescu and Maureen Ryan, David ... Sciences department, are among eight international co-authors of ... Ecology and the Environment . , Shale gas ...
(Date:7/31/2014)... tracing nearly 3,000 genes to the earliest common ... scientists have created an extensive "Tree of Lepidoptera" ... DNA sequencing. , Among the study,s more ... small moths than to large ones, which completely ... study also found that some insects once classified ...
Breaking Biology News(10 mins):Scientists warn time to stop drilling in the dark 2Scientists warn time to stop drilling in the dark 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3
... international research team co-led by a scientist at Fred ... behind the third most common form of muscular dystrophy. ... represent the latest in the team,s series of groundbreaking ... facioscapulohumeral muscular dystrophy, or FSHD., The team, co-led by ...
... geneticists sheds new light on how Facioscapulohumeral Muscular Dystrophy ... commonly known as FSHD, the devastating disease affects both ... inherited genetic disorder, yet sometimes appears spontaneously via new ... condition. "People with the condition experience progressive ...
... 2012 - Jackson Hole, Wyoming Scientists believe that ... primary genetic material, early,forms of life used RNA to ... life,rely on before RNA? The answer may be ... a hypothetical,backbone for Peptide Nucleic Acids, which have been ...
Cached Biology News:Researchers discover 2 genetic flaws behind common form of inherited muscular dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 2Mutations in genes that modify DNA packaging result in Facioscapulohumeral Muscular Dystrophy 3Weber State Scientists discover possible building blocks of ancient genetic systems 2
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
Anti-Goat HRP-AEC Cell & Tissue Staining Kit...
... provides all the materials necessary for the isolation ... antigen studies analysis. Kit Components: ... 5122) One bottle containing 220 mL of buffered ... (5X) - (Catalog No. 5113) One bottle containing ...
... CultureWell cell culture systems provide ... cultured cells for staining and ... silicone gaskets preassembled with standard ... plates. The entire system is ...
Biology Products: